News

UCSF Scientist Hosts Free Scleroderma Webinar on Lung Fibrosis

The University of California San Francisco (UCSF) will be hosting a free, live webinar entitled “Emerging Therapies in Pulmonary Fibrosis: Their Relevance for Scleroderma Patients,” to be conducted by the university’s Director of Biological Research for the Interstitial Lung Disease Program, Dr. Paul Wolters. It will be broadcasted on the Scleroderma…

Individualized Intervention Programs Benefit SSc Patients

A diagnosis of systemic sclerosis (SSc) can be extremely stressful for patients, and it is important that patients receive appropriate support to reduce emotional distress. Some patients may benefit from an interdisciplinary care program that incorporates physical therapy, occupational therapy, and specialized nurse care, according to a case study…

Apricus’ Investigational Treatment for Raynaud’s Phenomenon Receives Notice of Allowance of U.S. Patent Application

The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application to RayVa, a product candidate being developed by Apricus Biosciences for the treatment of Raynaud’s phenomenon, including the treatment of the condition secondary to Scleroderma. The Notice of Allowance means that the USPTO is now…